Lixte Biotechnology Holdings, Inc. (LIXT)

NASDAQ: LIXT · IEX Real-Time Price · USD
3.560
+0.040 (1.14%)
Mar 28, 2024, 10:21 AM EDT - Market open

Company Description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases.

The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.

It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases.

Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute.

Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings logo
Country United States
Founded 2005
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Bastiaan van der Baan M.Sc.

Contact Details

Address:
248 Route 25a, No. 2
East Setauket, New York 11733
United States
Phone 310 203 2902
Website lixte.com

Stock Details

Ticker Symbol LIXT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001335105
CUSIP Number 539319202
ISIN Number US5393193017
Employer ID 20-2903526
SIC Code 2834

Key Executives

Name Position
Bastiaan van der Baan M.Sc. President, Chief Executive Officer and Chairman of the Board of Directors
Robert Neal Weingarten Vice President and Chief Financial Officer
Eric J. Forman J.D. Vice President and Chief Operating Officer
Dr. James S. Miser M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 28, 2024 8-K Current Report
Mar 22, 2024 8-K Current Report
Mar 19, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 26, 2024 8-K Current Report
Jan 30, 2024 8-K Current Report
Nov 28, 2023 8-K Current Report
Nov 13, 2023 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Oct 17, 2023 8-K Current Report